期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2015年上半年美国FDA批准的新分子实体与评价:心血管系统疾病和癌症治疗用药 被引量：9

Updates of New Molecular Entities Approved by FDA in the First-Half of 2015: Cardiovascular and Cancer Drugs
暂未订购
导出
摘要 2015年上半年,FDA批准了14个新分子实体和新的治疗生物制品。本文介绍和评价心血管系统疾病和癌症治疗用药。 The US FDA approved 14 new molecular entities and new therapeutic biological products in the first- half of 2015. This article provides an update and evaluation of the new drugs approved for cardiovascular disease and cancer.
作者 孙树森 韩容 赵志刚
机构地区 美国西新英格兰大学药学院 首都医科大学附属北京天坛医院药剂科
出处 《药品评价》 CAS 2015年第16期6-12,共7页 Drug Evaluation
关键词 FDA 2015年上半年 新分子实体 心血管系统疾病 癌症 FDA 2015 New Molecular Entity Cardiovascular Disease Cancer
分类号 R972 [医药卫生—药品] R979.1 [医药卫生—药品]
  • 相关文献

参考文献16

  • 1孙树森,韩容,赵志刚.2015年上半年美国FDA批准的新分子实体与评价:消化系统疾病、皮肤病、感染和罕见病治疗用药[J].药品评价,2015,12(14):5-10. 被引量：11
  • 2Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism[J]. N Engl Med, 2013, 369(15): 1406-15.
  • 3Giugliano RE Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013, 369(22): 2093-104.
  • 4郭梦园,赵志刚,孙树森,李新刚.新型口服抗凝药与华法林临床应用的比较[J].药品评价,2015,12(4):24-29. 被引量：12
  • 5Swedberg K, Komaida M, B6hm M, etal. Ivabradine and outcomes in chronic heart failure(SHIFT): a randomised placebo-controlled study[J]. Lancet, 2010, 376(9744): 875-85.
  • 6Drugs for chronic heart failure[J]. Med Lett Drugs Ther, 2015, 57: 9.
  • 7Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure[J]. N Engl J Med, 2014, 371(12): 1091-9.
  • 8Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events[J]. N Engl J Med, 2013, 368(14): 1303-13.
  • 9Marino M, Rizzotti D, Leonardi S. Cangrelor: review of the drug and the CHAMPION programme (Including PHOENIX)[J]. CurrCardiol Rep, 2014, 16: 493-501.
  • 10Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of estrogen receptor-positive, HER2- negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study[J]. Lancet Oncol, 2015, 16(1): 25-35.

二级参考文献34

  • 1陈新谦,金有豫,汤光,主编.新编药物学第[M].第17版.第50章:抗凝血药.北京:人民卫生出版社.
  • 2European Heart Rhythm Association, Camm AJ, Kirchhof P, et al. Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC).Guidelines for the management of atrial fibrillation[J]. Eur Heart J, 2010, 31(19): 2369-2429.
  • 3Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011,365(10):883-891.
  • 4Granger CB, Alexander JH, McMurray J J, et al. Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med, 2011,365(11):981-992.
  • 5Larsen TB, Lip GY. Warfarin or noveloral anticoagulants for atrial fibrillation?[J]. Lancet, 2014, 383(9921): 931-933.
  • 6January CT, Wann ST, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. Circulation, 2014, 130(23): 2071-2104.
  • 7Warfarin sodium tablet[OL]. DailyMed. http://daitymed.nlm.nih. gov/dailymed/druglnfo.cfm. 2014-8-14/2014-12-20.
  • 8Dabigatran etexilate mesylate capsule[OL]. DailyMed. http:// dailymed.nlm.nih.gov/dailymed/druglnfo.cfm. 2014-11-14/2014- 12-20.
  • 9Rivaroxaban table[OL]. DailyMed. http://dailymed.nlm.nih.gov/ dailymed/druglnfo.cfm. 2014-11 - 14/2014-12-20.
  • 10Apixaban tablet[OL]. DailyMed. http://dailymed.nlm.nih.gov/ dailymed/druglnfo.efm.2014-8-14/2014-12-20.

共引文献20

同被引文献127

  • 1邹栩,顾凯.世界新药研发动向[J].中国新药杂志,2007,16(22):1821-1825. 被引量：5
  • 2MATTANO LA JR, MOSS TJ, EMERSON SG. Sensitive detection of rare circulating neuroblastoma ceils by the reverse tran- scriptasepolymerase chain reaction [ J ]. Cancer Res, 1992, 52 (17) : 4701 -4705.
  • 3CASTEL V, SEGURA V, CANETE A. Treatment of high-risk neuroblastoma with anti-GD2 antibodies [ J ]. Clin Trans Oncol, 2010, 12(12) : 788 -793.
  • 4HARA J. Development of treatment strategies for advanced neuroblastoma [J]. lnt J Clin Oncol, 2012, 17(3) : 196 -203.
  • 5United Therapeutics Corporation. UnituxinTM : US prescribinginformation [ EB/OL ]. [ 2015 - 03 - 25 ]. http ://www. accessdata. fda. gov/drugsatfda_docs/label/2015/125516s0001bl, pdf.
  • 6FDA. FDA approves first therapy for high-risk neuroblastoma [ EB/OL]. [2015 - 03 - 10]. http://www, fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm437460, htm.
  • 7CHERESH DA, PIERSCHBACHER MD. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins[ J ]. J Cell Biol, 1986, 102(3) :688 -696.
  • 8DESAI AV, FOX E, SMITH LM, et al. Pharmacokinetics of the chimeric anti-GD2 antibody, chl4. 18, in children with highrisk neuroblastoma[ J ]. Cancer Chemoth Pharmacol, 2014, 74 (5) : 1047 -1055.
  • 9YU AL, UTTENREUTHER-FISCHER MM, HUANG CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibodyChl4. 18 in patients with refractory neuroblastoma and osteosarcoma[ J ]. J Clin Oncol, 1998, 16 (6) : 2169 -2180.
  • 10YU AL, GILMAN AL, OZKAYNAK MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblas- toma[J]. NEnglJMed, 2010, 363(14): 1324-1334.

引证文献9

二级引证文献13

药品评价
2015年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部